| HOME >> BIOLOGY >> TECHNOLOGY |
SUNNYVALE, Calif., July 9 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the appointment of leading molecular epidemiologist and expert on Healthcare Associated Infections, Fred Tenover, Ph.D., as Senior Director of Scientific Affairs. Dr. Tenover will serve as a liaison with the Infection Control community and will lead Cepheid's Healthcare Associated Infection (HAI) Consortium program.
"The objective of the Cepheid HAI Consortium is to establish global connections between hospital laboratories and leading academic laboratories in order to track evolving drug resistance patterns, virulence determinants, and the emergence of new strains associated with specific HAIs. The resulting information will be used in the design of rapid and definitive new tests for HAIs and for ensuring that Cepheid's leadership position in this area is maintained and expanded," said David H. Persing, M.D., Ph.D., Chief Medical and Technology Officer at Cepheid. "Dr. Tenover is a noted microbiologist and authority on HAI-associated organisms and as such, is uniquely qualified to head Cepheid's HAI Consortium Program. I am extremely pleased to welcome such an accomplished scientist to our team and look forward to Fred's contribution as we continue to expand and refine our menu of molecular tests in this important developing market."
Dr. Tenover currently holds the position of Distinguished Consultant and Director, Office of Antimicrobial Resistance, Centers for Disease Control and Prevention, Atlanta, GA. In addition, Dr. Tenover is Director, Centers for Disease Control and Prevention/World Health Organization Collaborating Center for Global Antimicrobial Resistance Monitoring, Atlanta, GA and is Adjunct Professor in the Department of Epidemiology, Emory University School of Public Health, Atlanta, GA.
"Finding effective treatment for the increasing number of multiple antibiotic resistant HAIs has become a serious challenge for physicians not only in U.S. hospitals but around the world," said Dr. Tenover. "Providing physicians with the critical laboratory data they need to make decisions within a few hours instead of a few days will not only save lives but will help control the spread of infections in healthcare settings. I am delighted to have the opportunity to join forces with the distinguished team of scientists at Cepheid to confront the increasing burden of HAIs on human health."
Dr. Tenover is expected to join the Cepheid team in early October, 2008.
About Cepheid
Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.
This press release contains forward-looking statements that are not
purely historical regarding Cepheid's or its management's intentions,
beliefs, expectations and strategies for the future, including those
relating to future product development. Because such statements deal with
future events, they are subject to various risks and uncertainties, and
actual results could differ materially from the company's current
expectations. Factors that could cause actual results to differ materially
include risks and uncertainties such as those relating to: unforeseen
development and manufacturing problems; our ability to successfully obtain
regulatory approvals and introduce new products in the clinical market; the
performance and market acceptance of new products; the failure of products
to perform as expected, whether due to manufacturing errors, defects or
otherwise; the impact of competitive products and pricing; and underlying
market conditions worldwide. Readers should also refer to the section
entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007
and in its most recent quarterly report on Form 10-Q, each filed with the
Securities and Exchange Commission.
All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.
CONTACTS:
For Media For Cepheid Investor
Inquiries: Inquiries:
Jared Tipton Jacquie Ross
Cepheid Corporate Cepheid Investor
Communications Relations
408-400-8377 408-400-8329
jared.tipton@cepheid.com jacquie.ross@cepheid.com
'/>"/>
| SOURCE Cepheid Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. McKool Smith Adds Noted Litigator in New York
2. Life Sciences Industry Reaches Crossroad Say Noted Pillsbury Attorneys
3. Industry Veterans Join Molecular Imprints Management Team
4. New molecular imaging techniques may lead to advances in disease treatment
5. Michigan Tech scientist models molecular switch
6. 3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
7. Molecular changes in brain fluid give insight into brain-damaging disease
8. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
9. Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics
10. Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16
11. Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |